Center for Personal Cancer Vaccines Team
Our Staff
Director
Patrick Ott, MD, PhD, Associate Professor of Medicine, Clinical Director of Center for Immuno-oncology, IND holder of NeoVax
Advisors
Catherine J. Wu, MD, Professor of Medicine, Faculty Advisor of Translational Immunogenomics Lab, Chief, Division of Stem Cell Transplantation and Cellular Therapies
Ed Fritsch, PhD, Presidential Scholar
Principal Investigators
Toni Choueiri, MD, Renal Cell Carcinoma
Matthew Davids, MD, MMSc, and Inhye Ahn, MD, Chronic Lymphocytic Leukemia
Reid Merryman, MD, Follicular Lymphoma
Panagiotis (Panos) Konstantinopoulos, MD, PhD, Ovarian Cancer
Patrick Ott, MD, PhD, Melanoma
David Reardon, MD, and Bryan Iorgulescu, MD, MPH, Glioblastoma
Clinical and Research Management
Ambica Mehndiratta, Research Project Manager
Oriol Olive Noguer, Senior Clinical Trials Manager
Haley Greenslade, Research Project Manager
Our Dana-Farber/Harvard Medical School Collaborators
Translational Immunogenomics Laboratory (TIGL)
Our Experts in the News
- Toni Choueiri, Cathy Wu, and David Braun join the U.S. Department of Defense's new Academy of Kidney Cancer Investigators that will help advance kidney cancer research to understand resistance and develop new treatments that harness the immune system
- DFCI-Broad collaboration to improve neoantigen prediction: New tool could help researchers design better cancer vaccines
- NeoVax RCC clinical trial commences: Personalized vaccine to be tested with for patients with kidney cancer
- David Reardon's GBM NeoVax study published in Nature: Personal neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, new study shows
- NeoVax featured in Harvard Magazine issue on Precision Medicine
- Parker Institute for Cancer Immunotherapy Q&A with Cathy Wu
- Cathy Wu interviewed on WBUR's "This Moment in Cancer" special series
- Cathy Wu named one of "Nine Innovators to Watch in 2018" by Smithsonian Magazine
- Cathy Wu featured on Novel Targets podcast, "Cancer Vaccine Renaissance"
- Cathy Wu one of four Dana-Farber researchers joining the Parker Institute for Cancer Immunotherapy
- Cathy Wu and Patrick Ott publish first in-human study using a peptide-based neoantigen vaccine: Personal neoantigen vaccine prompts strong anti-tumor response in patients, new study shows